

The Broad Scope of Health Effects from Chronic Arsenic Exposure: Update on a Worldwide Public Health Problem

Marisa F. Naujokas,¹ Beth Anderson,² Habibur Ahsan,^{3,4,5} H. Vasken Aposhian,⁶ Joseph H. Graziano,⁷ Claudia Thompson,⁸ and William A. Suk²

¹MDB Inc., Durham, North Carolina, USA; ²Superfund Research Program, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH), Department of Health and Human Services (DHHS), Research Triangle Park, North Carolina, USA; ³Department of Health Studies, ⁴Department of Human Genetics, and ⁵Department of Medicine, The University of Chicago, Chicago, Illinois, USA; ⁶Department of Molecular and Cellular Biology, University of Arizona, Tucson, Arizona, USA; ⁷Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York, USA; ⁸Susceptibility and Population Health Branch, Superfund Research Program, NIEHS, NIH, DHHS, Research Triangle Park, North Carolina, USA

BACKGROUND: Concerns for arsenic exposure are not limited to toxic waste sites and massive poisoning events. Chronic exposure continues to be a major public health problem worldwide, affecting hundreds of millions of persons.

OBJECTIVES: We reviewed recent information on worldwide concerns for arsenic exposures and public health to heighten awareness of the current scope of arsenic exposure and health outcomes and the importance of reducing exposure, particularly during pregnancy and early life.

METHODS: We synthesized the large body of current research pertaining to arsenic exposure and health outcomes with an emphasis on recent publications.

DISCUSSION: Locations of high arsenic exposure via drinking water span from Bangladesh, Chile, and Taiwan to the United States. The U.S. Environmental Protection Agency maximum contaminant level (MCL) in drinking water is 10 µg/L; however, concentrations of > 3,000 µg/L have been found in wells in the United States. In addition, exposure through diet is of growing concern. Knowledge of the scope of arsenic-associated health effects has broadened; arsenic leaves essentially no bodily system untouched. Arsenic is a known carcinogen associated with skin, lung, bladder, kidney, and liver cancer. Dermatological, developmental, neurological, respiratory, cardiovascular, immunological, and endocrine effects are also evident. Most remarkably, early-life exposure may be related to increased risks for several types of cancer and other diseases during adulthood.

CONCLUSIONS: These data call for heightened awareness of arsenic-related pathologies in broader contexts than previously perceived. Testing foods and drinking water for arsenic, including individual private wells, should be a top priority to reduce exposure, particularly for pregnant women and children, given the potential for life-long effects of developmental exposure.

KEY WORDS: arsenic, arsenic health effects, cancer, chronic arsenic exposure, development, drinking water, skin lesions. *Environ Health Perspect* 121:295–302 (2013). <http://dx.doi.org/10.1289/ehp.1205875> [Online 3 January 2013]

Ongoing exposures to toxic chemicals such as arsenic continue to pose a significant threat to public health. The World Health Organization (WHO) estimates that > 200 million persons worldwide might be chronically exposed to arsenic in drinking water at concentrations above the WHO safety standard of 10 µg/L (WHO 2008) (Table 1). Arsenic is a metalloid element that is encountered primarily as arsenical compounds. Within these compounds, arsenic occurs in different valence states, the most common of which are As^{III} (arsenites) and As^V (arsenates). Arsenic in drinking water is typically found in the inorganic form, either as As^{III} or As^V, whereas arsenic in food is found in the organic and inorganic forms, depending on the specific food [Agency for Toxic Substances and Disease Registry (ATSDR) 2007; European Food Safety Authority (EFSA) 2009]. Sources of arsenic contamination include natural deposits as well as anthropogenic sources such as mining and electronics manufacturing processes and metal smelting (ATSDR 2007).

Arsenic holds the highest ranking on the current U.S. ATSDR 2011 substance priority

list (ATSDR 2011b) (Table 2). ATSDR ranks chemicals using an algorithm that translates potential public health hazards into a points-scaled system based on the frequency of occurrence at National Priority List (NPL) Superfund sites as well as toxicity and potential for human exposure. Arsenic tops the list in spite of the fact that this ranking does not include full consideration of exposure from drinking water, diet, copper-chromated arsenic-treated wood, coal- and wood-burning stoves, arsenical pesticides, and homeopathic remedies (ATSDR 2007, 2011b; Akter et al. 2005; EFSA 2009; Rose et al. 2007). Therefore, the threat to human health posed by arsenic is even greater than its top ATSDR ranking would suggest. In regard to toxicity, the International Agency for Research on Cancer (IARC) defines arsenic as a Group I known human carcinogen that also induces a wide array of other noncancer effects, leaving essentially no bodily system free from potential harm (ATSDR 2007; IARC 2012; National Research Council 2001; WHO 2008).

Here we synthesize the large body of current research pertaining to arsenic exposure and

health effects and emphasize the broadening scope of predicted and observed impacts of arsenic on public health. Understanding the wide range of these impacts drives home the importance of testing drinking-water sources and monitoring foods for arsenic. Whereas municipalities test public drinking-water sources, private wells can go untested. Recent data also raise concerns for arsenic exposure via foods including rice and organic brown rice syrup [Davis et al. 2012; EFSA 2009; Food and Drug Administration (FDA) 2012; Gilbert-Diamond et al. 2011; Jackson et al. 2012] as well as chicken feather meal products that are used in the human food system (Nachman et al. 2012).

Even as assessments of dietary exposure continue to unfold, drinking water remains a major concern for arsenic exposure. There are known, large-scale drinking-water contamination problems in countries such as Bangladesh (Ahsan et al. 2006; Argos et al. 2010, 2012; Smith et al. 2000b). However, chronic arsenic exposure is a concern in many parts of the world (Table 1). For example, arsenic concentrations in drinking water from some private wells in the United States are as high as 3,100 µg/L, which is in the range of the highest concentrations reported in Bangladesh (Nielsen et al. 2010; Yang et al. 2009). Yet detection of arsenic contamination even at these high levels remains problematic because it is tasteless, colorless, and odorless.

Given the large number of studies that address the broad range of information provided here, it is impractical to include all pertinent studies. Rather, we present a synthesis

Address correspondence to M. Naujokas, MDB Inc., 2525 Meridian Corporate Center, Suite 50, Durham, North Carolina 27713 USA. Telephone: (919) 794-4700. E-mail: naujokasmf@niehs.nih.gov

M.F.N. is supported through a contract with the National Institute of Environmental Health Sciences (NIEHS) Superfund Research Program (SRP) (contract GS-OOF-0001S, Health and Human Services order CR700013). H.A. is supported by National Institutes of Health and NIEHS SRP grants P42ES10349, RO1CA107431, and RO1CA102484. J.G. is supported by NIEHS SRP grant P42ES10349.

The authors declare they have no actual or potential competing financial interests.

Received 8 August 2012; accepted 21 December 2012.

of information and cite recent studies that help illustrate the breadth and scope of the problems. When available, we cite current reviews that can serve as a resource for a more complete listing of relevant resources, most often focusing on single health issues such as cardiovascular disease (States et al. 2009). Detailed discussions of arsenic exposure and health effects can be found elsewhere (ATSDR 2007; EFSA 2009; Gibb et al. 2011; States et al. 2011).

As awareness of arsenic exposure increases, so should knowledge of its health effects because the impact of chronic arsenic exposure on public health is substantial. In addition to skin lesions and skin cancer (ATSDR 2011a; Sengupta et al. 2008; Smith et al. 2000a), neurological, respiratory, cardiovascular, and developmental effects and more are linked to chronic arsenic exposure (Table 3) (Argos et al. 2012; Smith and Steinmaus 2009; States et al. 2011). Acute poisonings still occur but are uncommon (Bronstein et al. 2011). Arsenic renders its toxicity via numerous mechanisms: Arsenic is genotoxic and has multiple effects on cellular signaling, cellular proliferation, DNA structure, epigenetic regulation, and apoptosis (Flora 2011; Ren et al. 2011; States et al. 2011).

A wealth of data comes from ongoing epidemiological studies of large populations exposed to a wide range of arsenic levels in drinking water in regions such as Taiwan, Bangladesh, Chile, India, and Argentina (Ahsan et al. 2006; Argos et al. 2012; Chen CL et al. 2010a; Smith et al. 2011; Yuan et al. 2010). In Taiwan, a stable population in an arsenic-endemic region had been exposed to arsenic via drinking water since the 1900s [Chen CJ et al. 1988b, 1992; Gibb et al. 2011; Tseng 1977; U.S. Environmental Protection Agency (EPA) 2001; Wu et al. 1989]. In Bangladesh, tube wells were dug in the 1970s as a source of drinking water to avoid microbial

contamination, only to later learn that the tube wells are contaminated with naturally occurring arsenic (Smith et al. 2000b). Researchers established a cohort in Bangladesh with over 10,000 persons enrolled as part of the Health Effects of Arsenic Longitudinal Study (HEALS) (Ahsan et al. 2006; Argos et al. 2012). Researchers are also studying a population in Chile where some cities were exposed to high concentrations of arsenic for a defined, limited period of time (1958–1971), at which point, systems were installed to remove arsenic from drinking water (Biggs et al. 1998). This population is particularly well suited for studies related to latency periods for chronic diseases and susceptibility during development (Dauphine et al. 2011; Liaw et al. 2008; Marshall et al. 2007; Yuan et al. 2010). Major findings from these cohorts and other studies are described in the following sections.

In light of accumulated research, there is increasing awareness that arsenic exposure might be affecting more persons and contributing to more chronic disease than previously thought. In the HEALS cohort, approximately 21.4% of all deaths and 23.5% of deaths associated with chronic disease could be attributed to arsenic at > 10 µg/L in drinking water (Argos et al. 2010). Here we present an overview and synthesis of recent information on worldwide concerns for arsenic exposures and public health. The enormity of potential public health impacts is striking. Given this potential, testing and remediating arsenic in drinking water at the level of single private wells and reducing dietary exposure are critical to protecting public health.

Worldwide Concerns for Arsenic Exposure

Arsenic exposure is a major environmental public health concern worldwide and a primary concern for exposure is via drinking

water (Table 1). The WHO and Australia set or confirmed a guideline level of 10 µg/L for arsenic in drinking water in 2008 and 2011, respectively (National Health and Medical Research Council 2011; WHO 2008). The U.S. EPA promulgated that it lowered the maximum contaminant level (MCL) from 50 µg/L to 10 µg/L, effective in 2002 (U.S. EPA 2001). In many developing countries, including Bangladesh, 50 µg/L is still the commonly adopted guideline, primarily because of difficulties in remediating arsenic below that level (WHO 2008). The excess cancer risk associated with lifetime arsenic exposure at water concentrations of > 10 µg/L is approximately 1 in 300, which is 30–300 times higher than the cancer risks estimated for exposure to other known carcinogens in drinking water at concentrations equal to current U.S. drinking-water standards (Smith et al. 2002).

What is the extent of chronic exposure via drinking water? The answer varies greatly depending on regional and local sources of arsenic (Table 1). For example, in Maine, the U.S. Geological Survey reported that 18.4% of wells tested had > 10 µg/L arsenic and estimated that 24,000–44,000 households might be affected (Nielsen et al. 2010). A recent study predicted that 42.7% of the area of aquifers in the southwestern United States has arsenic concentrations of ≥ 10 µg/L, although portions of these areas are in remote regions (Anning et al. 2012). Of 63,000 wells tested in North Carolina, 1,436 (2.3%) had arsenic concentrations of > 10 µg/L with a maximum of 806 µg/L (Sanders et al. 2012). In comparison, in Bangladesh in 1998, shortly after discovery of arsenic contamination, it was estimated that up to 94% of tube wells in certain regions and 35% of all wells in the country contained > 50 µg/L arsenic (Smith et al. 2000b). In Chile, San Pedro de Atacama drew most of its public drinking water from the Vilama River, which contained approximately 600–680 µg/L arsenic, and some homes with

Table 1. Arsenic exposure concerns worldwide.

Country	Estimated exposed population (millions) ^a	Arsenic concentration in drinking water (µg/L)	References
Argentina	2.0	< 1 to 7,550	Bates et al. 2004; Moore et al. 2004; Steinmaus et al. 2010
Bangladesh	35–77	< 10 to > 2,500	Kinniburgh and Smedley 2001
Chile ^b	0.4	600 to 800	Ferreccio et al. 2000; Smith et al. 1998, 2000a
China	0.5–2.0	< 50 to 4,400	Yu et al. 2007
Ghana	< 0.1	< 2 to 175	Asante et al. 2007; Smedley 1996
India	> 1.0	< 10 to > 800	Acharyya et al. 1999
Mexico	0.4	5 to 43	Calderón et al. 2001; Camacho et al. 2011; Meza et al. 2004, 2005
Taiwan	NA	< 1 to > 3,000	Chen et al. 2010a, 2010b
United States	> 3.0	< 1 to > 3,100	Anning et al. 2012; Ayotte et al. 2003; Burgess et al. 2007; Nielsen et al. 2010; NRDC 2000; Peters 2008; Sanders et al. 2012; Thundiyil et al. 2007; Xue et al. 2010
Vietnam	> 3.0	< 0.1 to 810	Winkel et al. 2011

Abbreviations: NA, not available; NRDC, National Resources Defense Council.

^aEstimated number of persons exposed to > 10 µg/L arsenic in drinking water. Estimates were obtained from cited references and usually refer to a specific city or region within each country. The actual number of exposed persons in each country could be higher. ^bThe population in one region of Chile was exposed to high levels of arsenic from 1958 to 1971, and studies of long-term and latent effects are ongoing.

Table 2. The ATSDR 2011 substance priority list.

Rank	Substance name	Points	CAS number
1	Arsenic	1665.5	007440-38-2
2	Lead	1529.1	007439-92-1
3	Mercury	1460.9	007439-97-6
4	Vinyl chloride	1361.1	000075-01-4
5	Polychlorinated biphenyls (PCBs)	1344.1	001336-36-3
6	Benzene	1332.0	000071-43-2
7	Cadmium	1318.7	007440-43-9
8	Polycyclic aromatic hydrocarbons	1282.3	130498-29-2
9	Benzo[<i>a</i>]pyrene	1305.7	000050-32-8
10	Benzo[<i>b</i>]fluoranthene	1252.4	000205-99-2

This list was generated by the ATSDR (2011) using an algorithm that translates potential public health hazards into a points-scaled system based on the frequency of occurrence at NPL Superfund sites and on toxicity and potential for human exposure.

no public supply drew water from the San Pedro River, which contained 170 µg/L; in contrast, a town 40 km away had an average drinking-water arsenic concentration of 15 µg/L (Hopenhayn-Rich et al. 1996).

Testing is required to determine whether a given source of drinking water has high levels of arsenic. Even if the local municipality does not test private wells for arsenic, test kits are available worldwide through local municipalities, public health offices, and commercial sources accessible via the Internet (Water Quality Association 2012; Massachusetts Department of Environmental Protection 2011). Hot spots of arsenic contamination of drinking-water sources can occur because of proximity to naturally occurring arsenic found in certain types of bedrock and sediments as well as proximity to hazardous waste sites. Therefore, drinking-water sources with high arsenic concentrations can exist in very close proximity to sources with low arsenic concentrations, with differences noted even in neighboring individual wells.

Another source of growing concern for arsenic exposure is through diet. For persons with limited exposure to arsenic via drinking water, diet is the major source of exposure (EFSA 2009). Rice, organic rice syrup, fruits, juices, and other grains can contain significant amounts of arsenic (FDA 2012; Jackson et al. 2012; Norton et al. 2012). Furthermore, rice consumption has been shown to be associated with urinary arsenic levels in pregnant women and children (Davis et al. 2012; Gilbert-Diamond et al. 2011). Because of their level of consumption of rice products, children < 3 years of age are estimated to have the greatest exposures to arsenic via diet (EFSA 2009).

Health Outcomes of Arsenic Exposure

Dermatological effects. Cutaneous lesions are one of the best-known clinical manifestations of chronic arsenic exposure and can occur within months or after several years of exposure (Das and Sengupta 2008; WHO 2005). Clinical photos of different types of arsenic-associated lesions are shown in Figure 1. Melanosis (hyperpigmentation) is considered an early and more common manifestation (Figure 1A), whereas keratosis (Figure 1B) is considered a sensitive marker of more advanced stages of arsenicosis (Das and Sengupta 2008; Sengupta et al. 2008). Leucomelanosis (hypopigmentation) also occurs but less frequently than melanosis or keratosis. Arsenic-related melanosis can be diffuse or patchy, or exhibit a distinctive “rain drop” pattern, and these lesions often appear on the trunk of the body. Keratotic lesions tend to appear mainly on the palms and soles. Sudden increases in the size of keratotic lesions, or cracks or bleeding of lesions, suggest malignant transformation—often to squamous cell carcinoma (Figure 1C,D).

Analyses of numerous epidemiological studies of skin lesions suggest that most persons with skin lesions had consumed water with arsenic concentrations of > 100 µg/L, although lesions have been reported at arsenic concentrations of < 50 µg/L (Argos et al. 2011; Smith and Steinmaus 2009). Nutritional, economic, and smoking status are contributing factors for susceptibility to skin lesions as are sex and age, with a greater prevalence of skin lesions in older men (Pierce et al. 2010). A recent report from the HEALS prospective study found that the risk of skin lesions did not decrease after reducing exposure for up to several years (Argos et al. 2011). Therefore, lesions can appear several years after exposure diminishes. The vast majority of exposed individuals (even with high levels of chronic exposure) will not develop skin lesions but are still at risk of arsenic-related skin and internal cancers and other noncancer diseases (Argos et al. 2010; Chen Y et al. 2011; Parvez et al. 2010).

Arsenic exposure and cancer. Arsenic is a known carcinogen in skin, lung, bladder, liver, and kidney, with evidence suggesting lung cancer is the most common cause of arsenic-related mortality (IARC 2012; National Toxicology Program 2011). Skin cancer has long been associated with chronic arsenic exposure (ATSDR 2007; Yu et al. 2006). Squamous cell carcinoma *in situ* (Bowen’s disease; Figure 1C), invasive squamous cell carcinoma (Figure 1D), and basal cell carcinoma (Figure 1E) are the most common types of skin cancer associated with chronic arsenic exposure. Studies from arsenic-endemic regions of Taiwan revealed that the overall prevalence of skin cancer was 10.6 per 1,000 persons and was associated with increased arsenic drinking-water concentrations (Tseng 1977) and increased urinary concentrations of certain arsenic metabolites (Tseng 2007). In the United States, where arsenic exposure is generally lower, significantly increased risks for squamous cell and

Table 3. Arsenic affects a broad range of organs and systems.

Targets	Health effects	References
Skin	Skin lesions	Argos et al. 2011; Haque et al. 2003; Smith et al. 2000a
	Skin cancer	Tseng 1977, 2007; Yu et al. 2006
Developmental processes	Increased infant mortality	Milton et al. 2005; Rahman et al. 2010a
	Reduced birth weight	Rahman et al. 2009
	Altered DNA methylation of tumor promoter regions in cord blood and maternal leukocytes	Intarasunanont et al. 2012; Kile et al. 2012
	Neurological impairments in children	Dong and Su 2009; Hamadani et al. 2011; Wasserman et al. 2004, 2007
Nervous system	Early-life exposure associated with increased cancer risk as adults	Bates et al. 2004; Chen CL et al. 2010b; Liaw et al. 2008; Marshall et al. 2007; Su et al. 2011; Yuan et al. 2010
	Impaired intellectual function in children and adults	Hamadani et al. 2011; Wasserman et al. 2004, 2007; Dong and Su 2009
	Impaired motor function	Gong et al. 2011; Parvez et al. 2011
Respiratory system	Neuropathy	Vahidnia et al. 2007
	Increased mortality from Pulmonary tuberculosis	Smith et al. 2011
Cardiovascular system	Bronchiectasis	Smith et al. 2006
	Lung cancer	Heck et al. 2009; Marshall et al. 2007; Smith et al. 2009
	Coronary and ischemic heart disease	Chen Y et al. 2011; Gong and O’Byrne 2012
Liver, kidney, and bladder	Acute myocardial infarction	Yuan et al. 2007
	Hypertension	Abhyankar et al. 2012; Abir et al. 2012
	Liver cancer	Chen and Ahsan 2004; Chiu et al. 2004; Liaw et al. 2008; Liu and Waalkes 2008
Immune system	Kidney cancer	Bates et al. 2004; Yuan et al. 2010
	Bladder and other urinary cancers	Chen et al. 2010b; Chiou et al. 2001; Gibb et al. 2011; Marshall et al. 2007
	Altered immune-related gene expression and cytokine expression	Ahmed et al. 2011; Andrew et al. 2008; Kile et al. 2012
Endocrine system	Inflammation	Ahmed et al. 2011
	Increased infant morbidity from infectious diseases	Rahman et al. 2010b; Spivey 2011
	Diabetes	Chen et al. 2007; Del Razo et al. 2011; Islam et al. 2012; Jovanovic et al. 2012
Endocrine system	Impaired glucose tolerance in pregnant women	Ettlinger et al. 2009
	Disrupted thyroid hormone, retinoic acid, and glucocorticoid receptor pathways in mice and amphibians	Barr et al. 2009; Davey et al. 2007, 2008

The list of references is not intended to be comprehensive but rather to provide examples of health effects across multiple bodily systems.

basal cell carcinomas occurred in individuals in the top 97th percentile of toenail arsenic concentrations (Karagas et al. 2001), particularly among individuals carrying susceptible genotypes for the nucleotide excision repair genes (Applebaum et al. 2007).

Chronic arsenic exposure is also associated with an increased risk of lung cancer (IARC 2012). In the Chilean cohort that was exposed to high arsenic concentrations in drinking water (> 850 µg/L) for a limited period of time (1958–1971), the peak mortality rate ratio (MRR) for lung cancer was highest at 3.61 (95% CI: 3.13, 4.16) for men in 1992–1994 (Table 4), suggesting a 34- to 36-year latency period (Marshall et al. 2007). Arsenic is carcinogenic in the lung regardless of oral or inhalation pathways of exposure, and it is well established that lung cancer is associated with exposure to > 100 µg/L arsenic in drinking water. However, it is unclear whether such an association exists for exposure

to < 100 µg/L arsenic (Chen CL et al. 2010a; Heck et al. 2009; Putila and Guo 2011; Smith et al. 2009; Steinmaus et al. 2010).

Increasing evidence supports the hypothesis that arsenic exposure can increase cancer risks in other organs. Increased risk of bladder cancer is significantly associated with increasing arsenic exposure, particularly with longer exposure periods (> 40 years) and higher drinking-water concentrations (> 600 µg/L) (Chen CJ et al. 1992; Chen CL et al. 2010b; Chiou et al. 2001; Gibb et al. 2011; Marshall et al. 2007). For kidney cancer, mortality rates increased in a dose-dependent manner for drinking-water concentrations ranging from 170 to 800 µg/L in Taiwan (Chen CJ et al. 1988a); the MRRs at 800 µg/L were 196 for men and 37.0 for women. Results from other studies in Taiwan support this finding (Smith et al. 1992). More studies with larger sample sizes are warranted to evaluate associations at drinking-water concentrations of < 100 µg/L.

A causal association between arsenic exposure and liver cancer, particularly liver angiosarcoma, was suspected as early as 1957, and several studies have substantiated that suspicion (e.g., Liaw et al. 2008; Smith et al. 1992). A number of studies from the Taiwan cohort have demonstrated increases in liver cancer deaths with increasing concentrations of arsenic in drinking water. For example, a significant dose-dependent linear trend in MRRs for liver cancer was reported with increasing arsenic concentrations in drinking water ranging from 170 to 800 µg/L (Chen CJ et al. 1988a; Wu et al. 1989). Links between arsenic exposure and liver cancer have also been supported by other reports (Chen CL et al. 2010b; Chen and Ahsan 2004; Chiu et al. 2004; Liaw et al. 2008; Morales et al. 2000). Taking epidemiological, rodent, and *in vitro* studies together, the evidence shows that the liver is a target organ of arsenic carcinogenicity (Liu and Waalkes 2008).




Figure 1. Skin manifestations of chronic arsenic exposure. (A) Hyperpigmentation (melanosis); (B) hyperkeratosis (keratosis); (C) squamous cell carcinoma *in situ* (Bowen's disease); (D) invasive squamous cell carcinoma; and (E) basal cell cancer.

Table 4. Peak mortality ratios for internal cancers and bronchiectasis in Chilean cohort studies.

Disease	Reference	Peak mortality ratio (95% CI)	Type of mortality ratio	Subpopulation with peak ratio
Lung cancer	Marshall et al. 2007	3.61 (3.13, 4.16)	MRR	Men, 22–24 years after exposure reduction
Bladder cancer	Marshall et al. 2007	13.8 (7.74, 24.5)	MRR	Women, 22–24 years after exposure reduction
Childhood liver cancer	Liaw et al. 2008	14.1 (1.6, 126.2)	MRR	Girls born 1950–1957 (exposed during childhood), 0–19 years of age
Kidney cancer	Yuan et al. 2010	4.37 (2.98, 6.41)	MRR	Women, 21–25 years after exposure reduction
		9.52 (2.56, 24.4)	MRR	Women born 1950–1970 (exposed <i>in utero</i> and during childhood), 21–25 years after exposure reduction
Bronchiectasis	Smith et al. 2006	50.1 (20.0, 103)	SMR	Women born 1958–1970 (exposed <i>in utero</i> and during childhood), 18–29 years after exposure reduction

Abbreviations: MRR, mortality rate ratio; SMR, standardized mortality ratio. For the exposed group, arsenic concentrations in drinking water were high (about 870 µg/L) between 1958 and 1970, at which point, filtration systems were installed thereby lowering the arsenic exposure. At the time of exposure reduction, the exposed population ages ranged from prenatal through adulthood.

Other effects on multiple bodily systems.

A multitude of other health effects are linked to chronic arsenic exposure. These arsenic-associated health problems affect nearly every major organ and organ system in the body (Table 3). A comprehensive review of the literature for these effects is beyond the scope of this review; therefore, this section addresses the broad range of harmful effects of arsenic in the human body and makes apparent the impact of arsenic-contaminated drinking water on public health. Taken together, the body of data drives home the critical importance of monitoring for arsenic in food sources and drinking-water sources, including private wells.

Significant neurological impairments are evident in children and adults who exhibit impaired cognitive abilities and motor functions after arsenic exposure (Chen Y et al. 2009; Dong and Su 2009; Gong et al. 2011; Hamadani et al. 2011; Parvez et al. 2011; Vahidnia et al. 2007; Wasserman et al. 2004, 2007). Cognitive impairments were observed in children at 6 and 10 years of age (Wasserman et al. 2004, 2007). One recent study reported impairments in verbal and full-scale IQ in girls but not boys (Hamadani et al. 2011). In adults, arsenic exposure in drinking water is linked to significantly lower scores on tests of cognitive ability as well as lower education levels (Gong et al. 2011). Peripheral neuropathy and painful muscle spasms are also known to occur with arsenic exposure (Sengupta et al. 2008; Vahidnia et al. 2007).

In addition to lung cancer, chronic arsenic exposure is associated with other respiratory system effects. Mortality from pulmonary tuberculosis was increased in arsenic-exposed individuals in the Chilean cohort (Smith et al. 2011). In the same cohort, increased mortality from bronchiectasis was significant for those exposed to arsenic during early life with a standardized mortality ratio (SMR) of 50.1 (Table 4) (Smith et al. 2006). Reduced forced expiratory volume and forced vital capacity is associated with early-life exposure to arsenic, with a magnitude of reduction similar to smoking throughout adulthood (Dauphine et al. 2011). Other respiratory symptoms include chronic cough, blood in the sputum, and other breathing problems (Parvez et al. 2010).

The cardiovascular system is affected in several ways by arsenic (Abhyankar et al. 2012; Chen Y et al. 2009, 2011; States et al. 2009; Yuan et al. 2007). Cardiovascular effects include carotid atherosclerosis (Huang et al. 2009) and ischemic heart disease (Abhyankar et al. 2012; Chen Y et al. 2011; States et al. 2009). Furthermore, an association between hypertension and arsenic exposure is evident in some studies, and additional larger studies are needed to substantiate the link (Abhyankar et al. 2012; Abir et al. 2012).

Immune system effects of arsenic exposure are evident in several contexts. Effects include altered immune-related gene expression and cytokine production in lymphocytes (Andrew et al. 2008; Morzadec et al. 2012) and in lung (Lantz et al. 2007). Arsenic is significantly associated with increased infant morbidity from infectious diseases (Rahman et al. 2010b). Furthermore, maternal urinary arsenic during pregnancy is significantly associated with increased inflammation and reduced numbers of T cells as well as altered cytokine profiles in cord blood (Ahmed et al. 2011) and reduced thymic function in infants (Ahmed et al. 2012).

Multiple endocrine effects of arsenic exposure are suggested from studies in human and animal studies. These include affecting hormone regulation via the retinoic acid, thyroid hormone, and estrogen receptors (Barr et al. 2009; Davey et al. 2007, 2008; Erttinger et al. 2009; Smith and Steinmaus 2009; Watson and Yager 2007). Increased occurrence of diabetes is also linked to arsenic exposure, particularly at higher doses and with exposure periods of > 10 years (Chen CJ et al. 2007; Del Razo et al. 2011; Islam et al. 2012; Jovanovic et al. 2012).

Varied Susceptibilities

Genetic and nutritional factors in susceptibility. The variety of biological systems often simultaneously affected by arsenic is further complicated by varied individual susceptibilities to its toxic effects. For example, inter-individual variation in the ability to methylate arsenic is associated with differential susceptibility to the effects of arsenic exposure (Hall and Gamble 2012; Steinmaus et al. 2010). Genetic polymorphisms have also been shown to be a contributing factor (Agusa et al. 2012; Ahsan et al. 2007; Applebaum et al. 2007; Argos et al. 2012; Pierce et al. 2012; Porter et al. 2010; Reichard and Puga 2010). A recent large, comprehensive genome-wide association study identified specific genetic variations associated with risk for skin lesions as well as differences in arsenic metabolism (Pierce et al. 2012). Evidence is also building that nutritional factors, notably folate, appear to play an important role in arsenic methylation and elimination (Basu et al. 2011; Chen Y et al. 2009; Gamble et al. 2007; Hall and Gamble 2012; Pilsner et al. 2009). For example, low folate and hyperhomocysteinemia are associated with increased risk of skin lesions (Pilsner et al. 2009). Together, current information about arsenic metabolism across individuals sheds light on possibilities for new strategies for the prevention and amelioration of the toxicity of arsenic.

Susceptibility during development and long-term latency. Adverse pregnancy and developmental outcomes are associated with

early-life exposure to arsenic (Vahter 2008). Arsenic exposure is significantly associated with increased infant mortality and, in some studies, increased spontaneous abortion and stillbirth (Milton et al. 2005; Rahman et al. 2010a; von Ehrenstein et al. 2006) as well as reduced birth weight (Rahman et al. 2009). Early-life arsenic exposure is also associated with neurological impairments in children (Hamadani et al. 2011; Parvez et al. 2011; Wasserman et al. 2004, 2007). For example, motor function in children, as well as verbal and full-scale IQ in girls, are both inversely associated with arsenic exposure (Hamadani et al. 2011; Parvez et al. 2011). Prenatal exposure also affects the developing immune system. Maternal urinary arsenic concentrations are associated with increased inflammation as well as altered cytokine profiles in cord blood and reduced thymus size and function in newborns (Ahmed et al. 2011, 2012). Altered immune responses are consistent with the observation of increased risk for lower respiratory infections and diarrhea in infants with increasing arsenic exposure (Rahman et al. 2010b).

The impacts of early-life arsenic exposure can continue into adulthood (Vahter 2008). Exposure during pregnancy and childhood is associated with an increased occurrence and/or severity of lung disease, cardiovascular disease, and cancer in childhood and later in life, with evidence of decades-long latency periods for these health conditions (Table 4) (Dauphine et al. 2011; Liaw et al. 2008; Marshall et al. 2007; Smith et al. 2011; Yuan et al. 2010). Childhood liver cancer MRRs were 9–14 times higher for those exposed as young children as compared with controls (Liaw et al. 2008). Other reports of latency periods extending over 50 years include skin cancer (Haque et al. 2003), urinary cancers (Bates et al. 2004; Chen CL et al. 2010b; Marshall et al. 2007; Su et al. 2011), and lung cancer (Marshall et al. 2007; Su et al. 2011). For example, peak SMRs for childhood liver cancer and bronchiectasis were 14.1 and 50.1 times higher, respectively, for individuals exposed to arsenic *in utero* and during childhood as compared with individuals exposed during other periods of their lives (Table 4) (Smith et al. 2006). Bladder cancer mortality peaked 25–36 years from the initiation of exposure (Marshall et al. 2007), and kidney cancer MRR peaked 21–25 years from initiation of exposure and was highest for women (Yuan et al. 2010). Regarding noncancer health effects, early-life arsenic exposure is associated with increased adult mortality from pulmonary tuberculosis (Smith et al. 2011), bronchiectasis (Smith et al. 2006), and myocardial infarction (Yuan et al. 2007).

Together the data indicate a sensitivity during development to health effects that can be long lasting and latent for > 50 years. The

implications are profound and make it clear that every effort should be made to prevent exposure of pregnant women, women of child-bearing age, infants, and children to arsenic in order to prevent a multitude of health effects, particularly cancer, later in life.

Conclusions

Environmental health issues are not limited to toxic waste sites and poisoning events: some deleterious exposures come from naturally occurring substances, such as arsenic often found in drinking water. Arsenic affects multiple biological systems, sometimes years or decades after exposure reductions. Studies that reveal the complex nature of the origins and toxicity of arsenic highlight the importance of heightened awareness of arsenic-related health effects in broader contexts than previously perceived. In spite of current efforts, over 200 million persons globally are at risk of arsenic exposure at levels of concern for human health. Although specific regulatory levels might be debatable, all would agree that minimizing arsenic exposure is the best solution, especially prenatal and early-life exposure. Therefore, testing drinking water for arsenic is particularly important for pregnant women and women of childbearing age, given the potential for neurological and other lifelong effects of early-life exposure. The return on the investment can be substantial when measured in the reduced incidence of chronic disease and reduced rates of cancer worldwide.

REFERENCES

- Abhyankar LN, Jones MR, Guallar E, Navas-Acien A. 2012. Arsenic exposure and hypertension: a systematic review. *Environ Health Perspect* 120:494–500.
- Abir T, Rahman B, D'Este C, Farooq A, Milton AH. 2012. The association between chronic arsenic exposure and hypertension: a meta-analysis. *J Toxicol* 2012:198793; doi:10.1155/2012/198793 [Online 8 March 2012].
- Acharyya SK, Chakraborty P, Lahiri S, Raymahashay BC, Guha S, Bhowmik A. 1999. Arsenic poisoning in the Ganges delta [Brief Discussion]. *Nature* 401(6753):545.
- Agusa T, Kunito T, Tue NM, Lan VT, Fujihara J, Takeshita H, et al. 2012. Individual variations in arsenic metabolism in Vietnamese: the association with arsenic exposure and GSTP1 genetic polymorphism. *Metalomics* 4(1):91–100.
- Ahmed S, Ahsan KB, Kippler M, Mily A, Wagatsuma Y, Hoque AM, et al. 2012. *In utero* arsenic exposure is associated with impaired thymic function in newborns possibly via oxidative stress and apoptosis. *Toxicol Sci* 129(2):305–314.
- Ahmed S, Khoda SM, Rekha RS, Gardner RM, Ameer SS, Moore S, et al. 2011. Arsenic-associated oxidative stress, inflammation, and immune disruption in human placenta and cord blood. *Environ Health Perspect* 119:258–264.
- Ahsan H, Chen Y, Kibriya MG, Slavkovich V, Parvez F, Jasmine F, et al. 2007. Arsenic metabolism, genetic susceptibility, and risk of premalignant skin lesions in Bangladesh. *Cancer Epidemiol Biomarkers Prev* 16(6):1270–1278.
- Ahsan H, Chen Y, Parvez F, Argos M, Hussain AI, Momotaj H, et al. 2006. Health Effects of Arsenic Longitudinal Study (HEALS): description of a multidisciplinary epidemiologic investigation. *J Expo Sci Environ Epidemiol* 16(2):191–205.
- Akter KF, Owens G, Davey DE, Naidu R. 2005. Arsenic speciation and toxicity in biological systems. *Rev Environ Contam Toxicol* 184:97–149.
- Andrew AS, Jewell DA, Mason RA, Whitfield ML, Moore JH, Karagas MR. 2008. Drinking-water arsenic exposure modulates gene expression in human lymphocytes from a U.S. population. *Environ Health Perspect* 116:524–531.
- Anning DW, Paul AP, McKinney TS, Huntington JM, Bexfield LM, Thiros SA. 2012. Predicted Nitrate and Arsenic Concentrations in Basin-Fill Aquifers of the Southwestern United States. Available: <http://pubs.usgs.gov/sir/2012/5065/> [accessed 1 October 2012].
- Applebaum KM, Karagas MR, Hunter DJ, Catalano PJ, Byler SH, Morris S, et al. 2007. Polymorphisms in nucleotide excision repair genes, arsenic exposure, and non-melanoma skin cancer in New Hampshire. *Environ Health Perspect* 115:1231–1236.
- Argos M, Ahsan H, Graziano JH. 2012. Arsenic and human health: epidemiologic progress and public health implications. *Rev Environ Health*; doi:10.1515/revheh-2012-0021 [Online 10 September 2012].
- Argos M, Kalra T, Pierce BL, Chen Y, Parvez F, Islam T, et al. 2011. A prospective study of arsenic exposure from drinking water and incidence of skin lesions in Bangladesh. *Am J Epidemiol* 174(2):185–194.
- Argos M, Kalra T, Rathouz PJ, Chen Y, Pierce B, Parvez F, et al. 2010. Arsenic exposure from drinking water, and all-cause and chronic-disease mortalities in Bangladesh (HEALS): a prospective cohort study. *Lancet* 376(9737):252–258.
- Asante KA, Agusa T, Subramanian A, Ansa-Asare OD, Biney CA, Tanabe S. 2007. Contamination status of arsenic and other trace elements in drinking water and residents from Tarkwa, a historic mining township in Ghana. *Chemosphere* 68(8):1513–1522.
- ATSDR (Agency for Toxic Substances and Disease Registry). 2007. Arsenic Toxicological Profile. Atlanta, GA:ATSDR. Available: <http://www.atsdr.cdc.gov/ToxProfiles/tp.asp?id=22&tid=3> [accessed 2 October 2012].
- ATSDR (Agency for Toxic Substances and Disease Registry). 2011a. Case Studies in Environmental Medicine: Arsenic Toxicity. Atlanta, GA:ATSDR. Available: <http://www.atsdr.cdc.gov/csem/csem.asp?csem=1&po=0> [accessed 2 October 2012].
- ATSDR (Agency for Toxic Substances and Disease Registry). 2011b. The ATSDR 2011 Substance Priority List. Atlanta, GA:ATSDR. Available: <http://www.atsdr.cdc.gov/SPL/index.html> [accessed 2 October 2012].
- Ayotte JD, Montgomery DL, Flanagan SM, Robinson KW. 2003. Arsenic in groundwater in eastern New England: occurrence, controls, and human health implications. *Environ Sci Technol* 37(10):2075–2083.
- Barr FD, Krohmer LJ, Hamilton JW, Sheldon LA. 2009. Disruption of histone modification and CARM1 recruitment by arsenic represses transcription at glucocorticoid receptor-regulated promoters. *PLoS One* 4(8):e6766; doi:10.1371/journal.pone.0006766 [Online 27 August 2009].
- Basu A, Mitra S, Chung J, Guha Mazumder DN, Ghose N, Kalman DA, et al. 2011. Creatinine, diet, micronutrients, and arsenic methylation in West Bengal, India. *Environ Health Perspect* 119:1308–1313.
- Bates MN, Rey OA, Biggs ML, Hopenhayn C, Moore LE, Kalman D, et al. 2004. Case-control study of bladder cancer and exposure to arsenic in Argentina. *Am J Epidemiol* 159(4):381–389.
- Biggs ML, Haque R, Moore L, Smith A, Ferreccio C, Hopenhayn-Rich C. 1998. Arsenic-laced water in Chile [Letter]. *Science* 281(5378):785.
- Bronstein AC, Spyster DA, Cantilena LR Jr, Green JL, Rumack BH, Dart RC. 2011. 2010 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 28th Annual Report. *Clin Toxicol* 49(10):910–941.
- Burgess JL, Meza MM, Josyula AB, Poplin GS, Kopplin MJ, McClellan HE, et al. 2007. Environmental arsenic exposure and urinary 8-OHdG in Arizona and Sonora. *Clin Toxicol* 45(5):490–498.
- Calderón J, Navarro ME, Jimenez-Capdeville ME, Santos-Diaz MA, Golden A, Rodriguez-Leyva I, et al. 2001. Exposure to arsenic and lead and neuropsychological development in Mexican children. *Environ Res* 85(2):69–76.
- Camacho LM, Gutiérrez M, Alarcón-Herrera MT, Villalba Mde L, Deng S. 2011. Occurrence and treatment of arsenic in groundwater and soil in northern Mexico and southwestern USA. *Chemosphere* 83(3):211–225.
- Chen CJ, Chen CW, Wu MM, Kuo TL. 1992. Cancer potential in liver, lung, bladder and kidney due to ingested inorganic arsenic in drinking water. *Brit J Cancer* 66(5):888–892.
- Chen CJ, Kuo TL, Wu MM. 1988a. Arsenic and cancers. *Lancet* 1(8582):414–415.
- Chen CJ, Wang SL, Chiou JM, Tseng CH, Chiou HY, Hsueh YM, et al. 2007. Arsenic and diabetes and hypertension in human populations: a review. *Toxicol Applied Pharmacol* 222(3):298–304.
- Chen CJ, Wu MM, Lee SS, Wang JD, Cheng SH, Wu HY. 1988b. Atherogenicity and carcinogenicity of high-arsenic artesian well water: multiple risk factors and related malignant neoplasms of blackfoot disease. *Arteriosclerosis* 8(5):452–460.
- Chen CL, Chiou HY, Hsu LI, Hsueh YM, Wu MM, Chen CJ. 2010a. Ingested arsenic, characteristics of well water consumption and risk of different histological types of lung cancer in northeastern Taiwan. *Environ Res* 110(5):455–462.
- Chen CL, Chiou HY, Hsu LI, Hsueh YM, Wu MM, Wang YH, et al. 2010b. Arsenic in drinking water and risk of urinary tract cancer: a follow-up study from northeastern Taiwan. *Cancer Epidemiol Biomarkers Prev* 19(1):101–110.
- Chen Y, Ahsan H. 2004. Cancer burden from arsenic in drinking water in Bangladesh. *Am J Public Health* 94(5):741–744.
- Chen Y, Graziano JH, Parvez F, Liu M, Slavkovich V, Kalra T, et al. 2011. Arsenic exposure from drinking water and mortality from cardiovascular disease in Bangladesh: prospective cohort study. *BMJ* 342:d2431; doi:10.1136/bmj.d2431 [Online 5 May 2011].
- Chen Y, Parvez F, Gamble M, Islam T, Ahmed A, Argos M, et al. 2009. Arsenic exposure at low-to-moderate levels and skin lesions, arsenic metabolism, neurological functions, and biomarkers for respiratory and cardiovascular diseases: review of recent findings from the Health Effects of Arsenic Longitudinal Study (HEALS) in Bangladesh. *Toxicol Appl Pharmacol* 239(2):184–192.
- Chiou HY, Chiou ST, Hsu YH, Chou YL, Tseng CH, Wei ML, et al. 2001. Incidence of transitional cell carcinoma and arsenic in drinking water: a follow-up study of 8,102 residents in an arseniasis-endemic area in northeastern Taiwan. *Am J Epidemiol* 153(5):411–418.
- Chiu HF, Ho SC, Wang LY, Wu TN, Yang CY. 2004. Does arsenic exposure increase the risk for liver cancer? *J Toxicol Environ Health A* 67(19):1491–1500.
- Das NK, Sengupta SR. 2008. Arsenicosis: diagnosis and treatment. *Indian J Dermatol Venereol Leprol* 74(6):571–581.
- Dauphine DC, Ferreccio C, Guntur S, Yuan Y, Hammond SK, Balmes J, et al. 2011. Lung function in adults following *in utero* and childhood exposure to arsenic in drinking water: preliminary findings. *Int Arch Occup Environ Health* 84(6):591–600.
- Davey JC, Bodwell JE, Gosse JA, Hamilton JW. 2007. Arsenic as an endocrine disruptor: effects of arsenic on estrogen receptor-mediated gene expression *in vivo* and in cell culture. *Toxicol Sci* 98(1):75–86.
- Davey JC, Nomikos AP, Wujcik-Ryan M, Sherman JR, Ingram L, Batki C, et al. 2008. Arsenic as an endocrine disruptor: arsenic disrupts retinoic acid receptor- and thyroid hormone receptor-mediated gene regulation and thyroid hormone-mediated amphibian tail metamorphosis. *Environ Health Perspect* 116:165–172.
- Davis MA, Mackenzie TA, Cottingham KL, Gilbert-Diamond D, Punshon T, Karagas MR. 2012. Rice consumption and urinary arsenic concentrations in U.S. children. *Environ Health Perspect* 120:1418–1424.
- Del Razo L, García-Vargas G, Valenzuela O, Castellanos E, Sánchez-Peña L, Currier J, et al. 2011. Exposure to arsenic in drinking water is associated with increased prevalence of diabetes: a cross-sectional study in the Zimapán and Lagunera regions in Mexico. *Environ Health* 10(1):73–84.
- Dong J, Su SY. 2009. The association between arsenic and children's intelligence: a meta-analysis. *Biol Trace Elem Res* 129(10):88–93.
- EFSA (European Food Safety Authority). 2009. Scientific Opinion on Arsenic in Food. *EFSA J* 7(10):60–71.
- Ettinger AS, Zota AR, Amarasiriwardena CJ, Hopkins MR, Schwartz J, Hu H, et al. 2009. Maternal arsenic exposure and impaired glucose tolerance during pregnancy. *Environ Health Perspect* 117:1059–1064.
- FDA (Food and Drug Administration). 2012. Arsenic in Rice. Available: <http://www.fda.gov/Food/FoodSafety/FoodContaminantsAdulteration/Metals/ucm319870.htm> [accessed 1 October 2012].
- Ferreccio C, Gonzalez C, Milosavljevic V, Marshall G, Sancha AM, Smith AH. 2000. Lung cancer and arsenic concentrations in drinking water in Chile. *Epidemiology* 11(6):673–679.
- Flora SJ. 2011. Arsenic-induced oxidative stress and its reversibility. *Free Radic Biol Med* 51(2):257–281.
- Gamble M, Liu X, Slavkovich V, Pilsner JR, Ilievski V, Factor-Litvak P, et al. 2007. Folic acid supplementation lowers blood arsenic. *Am J Clin Nutr* 86(4):1202–1209.

- Gibb H, Haver C, Gaylor D, Ramasamy S, Lee JS, Lobdell D, et al. 2011. Utility of recent studies to assess the National Research Council 2001 estimates of cancer risk from ingested arsenic. *Environ Health Perspect* 119:284–290.
- Gilbert-Diamond D, Cottingham KL, Gruber JF, Punshon T, Sayarath V, Gandolfi AJ, et al. 2011. Rice consumption contributes to arsenic exposure in U.S. women. *Proc Natl Acad Sci USA* 108(51):20656–20660.
- Gong G, Hargrave KA, Hobson V, Spallholz J, Boylan M, Lefforge D, et al. 2011. Low-level groundwater arsenic exposure impacts cognition: a project FRONTIER study. *J Environ Health* 74(2):16–22.
- Gong G, O'Bryant SE. 2012. Low-level arsenic exposure, AS3MT gene polymorphism and cardiovascular diseases in rural Texas counties. *Environ Res* 113:52–57.
- Hall MN, Gamble MV. 2012. Nutritional manipulation of one-carbon metabolism: effects on arsenic methylation and toxicity. *J Toxicol* 2012:595307, doi:10.1155/2012/595307 [Online 14 March 2012].
- Hamadani JD, Tofail F, Nermell B, Gardner R, Shiraji S, Bottai M, et al. 2011. Critical windows of exposure for arsenic-associated impairment of cognitive function in pre-school girls and boys: a population-based cohort study. *Int J Epidemiol* 40(6):1593–1604.
- Haque R, Mazumder DN, Samanta S, Ghosh N, Kalman D, Smith MM, et al. 2003. Arsenic in drinking water and skin lesions: dose-response data from West Bengal, India. *Epidemiology* 14(2):174–182.
- Heck JE, Andrew AS, Onega T, Rigas JR, Jackson BP, Karagas MR, et al. 2009. Lung cancer in a U.S. population with low to moderate arsenic exposure. *Environ Health Perspect* 117:1718–1723.
- Hopenhayn-Rich C, Biggs ML, Smith AH, Kalman DA, Moore LE. 1996. Methylation study of a population environmentally exposed to arsenic in drinking water. *Environ Health Perspect* 104:620–628.
- Huang YL, Hsueh YM, Huang YK, Yip PK, Yang MH, Chen CJ. 2009. Urinary arsenic methylation capability and carotid atherosclerosis risk in subjects living in arsenicosis-hyperendemic areas in southwestern Taiwan. *Sci Total Environ* 407(8):2608–2614.
- IARC (International Agency for Research on Cancer). 2012. A Review of Human Carcinogens: Arsenic, Metals, Fibres, and Dusts. Lyon:World Health Organization Press. Available: <http://monographs.iarc.fr/ENG/Monographs/vol100C/> [accessed 2 October 2012].
- Intarasunanont P, Navasumrit P, Woraprasit S, Chaisatra K, Suk WA, Mahidol C, et al. 2012. Effects of arsenic exposure on DNA methylation in cord blood samples from newborn babies and in a human lymphoblast cell line. *Environ Health* 11(1):31; doi:10.1186/1476-069X-11-31 [Online 2 May 2012].
- Islam MRD, Khan IP, Hassan SMD, McEvoy MM, D'Este CP, Attia JP, et al. 2012. Association between type 2 diabetes and chronic arsenic exposure in drinking water: a cross sectional study in Bangladesh. *Environ Health* 11(1):38; doi:10.1186/1476-069X-11-38 [Online 7 June 2012].
- Jackson BP, Taylor VF, Karagas MR, Punshon T, Cottingham KL. 2012. Arsenic, organic foods, and brown rice syrup. *Environ Health Perspect* 120:623–626.
- Jovanovic D, Rasic-Milutinovic Z, Paunovic K, Jakovljevic B, Plavsic S, Milosevic J. 2012. Low levels of arsenic in drinking water and type 2 diabetes in Middle Banat region, Serbia. *Int J Hyg Environ Health*; doi:10.1016/j.ijheh.2012.01.001 [Online 10 February 2012].
- Karagas MR, Stukel TA, Morris JS, Tosteson TD, Weiss JE, Spencer SK, et al. 2001. Skin cancer risk in relation to toenail arsenic concentrations in a U.S. population-based case-control study. *Am J Epidemiol* 153(6):559–565.
- Kile ML, Baccarelli A, Hoffman E, Tarantini L, Quamruzzaman Q, Rahman M, et al. 2012. Prenatal arsenic exposure and DNA methylation in maternal and umbilical cord blood leukocytes. *Environ Health Perspect* 120:1061–1066.
- Kinniburgh D, Smedley P. 2001. Arsenic Contamination of Groundwater in Bangladesh. Vol. 2: Final Report. Keyword: British Geological Survey and Department of Public Health Engineering (Bangladesh). Available: <http://www.bgs.ac.uk/downloads/directDownload.cfm?id=2223&noexcl=true&t=Phase%20%20Volume%20%203A%20Final%20Report%20cover%2C%20preliminary%20> [accessed 23 January 2013].
- Lantz RC, Lynch BJ, Boitano S, Poplin GS, Littau S, Tsapralis G, et al. 2007. Pulmonary biomarkers based on alterations in protein expression after exposure to arsenic. *Environ Health Perspect* 115:586–591.
- Liaw J, Marshall G, Yuan Y, Ferreccio C, Steinmaus C, Smith AH. 2008. Increased childhood liver cancer mortality and arsenic in drinking water in northern Chile. *Cancer Epidemiol Biomarkers Prev* 17(8):1982–1987.
- Liu J, Waalkes MP. 2008. Liver is a target of arsenic carcinogenesis. *Toxicol Sci* 105(1):24–32.
- Marshall G, Ferreccio C, Yuan Y, Bates MN, Steinmaus C, Selvin S, et al. 2007. Fifty-year study of lung and bladder cancer mortality in Chile related to arsenic in drinking water. *J Natl Cancer Inst* 99(12):920–928.
- Massachusetts Department of Environmental Protection. 2011. Certified Laboratories for Testing Arsenic & Uranium. Available: <http://www.mass.gov/dep/water/drinking/au/aulabs.htm> [accessed 16 December 2012].
- Meza MM, Kopplin MJ, Burgess JL, Gandolfi AJ. 2004. Arsenic drinking water exposure and urinary excretion among adults in the Yaqui Valley, Sonora, Mexico. *Environ Res* 96(2):119–126.
- Meza MM, Yu L, Rodriguez YY, Guild M, Thompson D, Gandolfi AJ, et al. 2005. Developmentally restricted genetic determinants of human arsenic metabolism: association between urinary methylated arsenic and CYT19 polymorphisms in children. *Environ Health Perspect* 113:775–781.
- Milton AH, Smith W, Rahman B, Hasan Z, Kulsum U, Dear K, et al. 2005. Chronic arsenic exposure and adverse pregnancy outcomes in Bangladesh. *Epidemiology* 16(1):82–86.
- Moore LE, Wiencke JK, Bates MN, Zheng S, Rey OA, Smith AH. 2004. Investigation of genetic polymorphisms and smoking in a bladder cancer case-control study in Argentina. *Cancer Lett* 211(2):199–207.
- Morales KH, Ryan L, Kuo TL, Wu MM, Chen CJ. 2000. Risk of internal cancers from arsenic in drinking water. *Environ Health Perspect* 108:655–661.
- Morzadec C, Bouezzedine F, Macooh M, Fardel O, Vernhet L. 2012. Inorganic arsenic impairs proliferation and cytokine expression in human primary T lymphocytes. *Toxicology* 300(1–2):46–56.
- Nachman KE, Raber G, Francesconi KA, Navas-Acien A, Love DC. 2012. Arsenic species in poultry feather meal. *Sci Total Environ* 417–418:183–188.
- National Health and Medical Research Council. 2011. National Water Quality Management Strategy: Australian Drinking Water Guidelines 6. Canberra:National Health and Medical Research Council. Available: <http://www.nhmrc.gov.au/guidelines/publications/eh52> [accessed 2 October 2012].
- National Research Council. 2001. Arsenic in Drinking Water: 2001 Update. Washington, DC:National Academy Press.
- National Toxicology Program. 2011. Report on Carcinogens, 12th ed. Research Triangle Park, NC:NTP. Available: <http://ntp.niehs.nih.gov/ntp/roc/twelfth/profiles/Arsenic.pdf> [accessed 2 October 2012].
- Nielsen MG, Lombard PJ, Schalk LK. 2010. Assessment of arsenic concentrations in domestic well water, by town, in Maine, 2005–09: U.S. Geological Survey Scientific Investigations Report 2010–5199. Available: <http://pubs.usgs.gov/sir/2010/5199/> [accessed 2 October 2012].
- Norton GJ, Pinson SR, Alexander J, McKay S, Hansen H, Duan GL, et al. 2012. Variation in grain arsenic assessed in a diverse panel of rice (*Oryza sativa*) grown in multiple sites. *New Phytol* 193(3):650–664.
- NRDC (National Resources Defense Council). 2000. Arsenic and old laws: a scientific and public health analysis of arsenic occurrence in drinking water, its health effects, and EPA's outdated arsenic tap water standard. Available: <http://www.nrdc.org/water/drinking/arsenic/aolinx.asp> [accessed 2 October 2012].
- Parvez F, Chen Y, Brandt-Rauf PW, Slavkovich V, Islam T, Ahmed A, et al. 2010. A prospective study of respiratory symptoms associated with chronic arsenic exposure in Bangladesh: findings from the Health Effects of Arsenic Longitudinal Study (HEALS). *Thorax* 65(6):528–533.
- Parvez F, Wasserman GA, Factor-Litvak P, Liu X, Slavkovich V, Siddique AB, et al. 2011. Arsenic exposure and motor function among children in Bangladesh. *Environ Health Perspect* 119:1665–1670.
- Peters SC. 2008. Arsenic in groundwaters in the Northern Appalachian Mountain belt: a review of patterns and processes. *J Contam Hydrol* 99(1–4):8–21.
- Pierce BL, Argos M, Chen Y, Melkonian S, Parvez F, Islam T, et al. 2010. Arsenic exposure, dietary patterns, and skin lesion risk in Bangladesh: a prospective study. *Am J Epidemiol* 173(3):345–354.
- Pierce BL, Kibriya MG, Tong L, Jasmine F, Argos M, Roy S, et al. 2012. Genome-wide association study identifies chromosome 10q24.32 variants associated with arsenic metabolism and toxicity phenotypes in Bangladesh. *PLoS Genet* 8(2):e1002522; doi:10.1371/journal.pgen.1002522 [Online 23 February 2012].
- Pilsner JR, Liu X, Ahsan H, Ilievski V, Slavkovich V, Levy D, et al. 2009. Folate deficiency, hyperhomocysteinemia, low urinary creatinine, and hypomethylation of leukocyte DNA are risk factors for arsenic-induced skin lesions. *Environ Health Perspect* 117:254–260.
- Porter KE, Basu A, Hubbard AE, Bates MN, Kalman D, Rey O, et al. 2010. Association of genetic variation in cystathionine- β -synthase and arsenic metabolism. *Environ Res* 110:580–587.
- Putla JJ, Guo NL. 2011. Association of arsenic exposure with lung cancer incidence rates in the United States. *PLoS One*. 6(10):e25886; doi:10.1371/journal.pone.0025886 [Online 18 October 2011].
- Rahman A, Persson LA, Nermell B, El Arifeen S, Ekstrom EC, Smith AH, et al. 2010a. Arsenic exposure and risk of spontaneous abortion, stillbirth, and infant mortality. *Epidemiology* 21(6):797–804.
- Rahman A, Vahter M, Ekstrom EC, Persson LA. 2010b. Arsenic exposure in pregnancy increases the risk of lower respiratory tract infection and diarrhea during infancy in Bangladesh. *Environ Health Perspect* 119:719–724.
- Rahman A, Vahter M, Smith AH, Nermell B, Yunus M, El Arifeen S, et al. 2009. Arsenic exposure during pregnancy and size at birth: a prospective cohort study in Bangladesh. *Am J Epidemiol* 169(3):304–312.
- Reichard JF, Puga A. 2010. Effects of arsenic exposure on DNA methylation and epigenetic gene regulation. *Epigenomics* 2(1):87–104.
- Ren X, McHale CM, Skibola CF, Smith AH, Smith MT, Zhang L. 2011. An emerging role for epigenetic dysregulation in arsenic toxicity and carcinogenesis. *Environ Health Perspect* 119:11–19.
- Rose M, Lewis J, Langford N, Baxter M, Origgi S, Barber M, et al. 2007. Arsenic in seaweed—forms, concentration and dietary exposure. *Food Chem Toxicol* 45(7):1263–1267.
- Sanders AP, Messier KP, Shehee M, Rudo K, Serre ML, Fry RC. 2012. Arsenic in North Carolina: public health implications. *Environ Int* 38(1):10–16.
- Sengupta SR, Das NK, Datta PK. 2008. Pathogenesis, clinical features and pathology of chronic arsenicosis. *Indian J Dermatol Venereol Leprol* 74(6):559–570.
- Smedley P. 1996. Arsenic in rural groundwater in Ghana. *J African Earth Sci* 22:459–470.
- Smith AH, Arroyo AP, Mazumder DN, Kosnett MJ, Hernandez AL, Beeris M, et al. 2000a. Arsenic-induced skin lesions among Atacameño people in Northern Chile despite good nutrition and centuries of exposure. *Environ Health Perspect* 108:617–620.
- Smith AH, Ercumen A, Yuan Y, Steinmaus CM. 2009. Increased lung cancer risks are similar whether arsenic is ingested or inhaled. *J Expo Sci Environ Epidemiol* 19(4):343–348.
- Smith AH, Goycolea M, Haque R, Biggs ML. 1998. Marked increase in bladder and lung cancer mortality in a region of Northern Chile due to arsenic in drinking water. *Am J Epidemiol* 147(7):660–669.
- Smith AH, Hopenhayn-Rich C, Bates MN, Goeden HM, Hertz-Picciotto I, Duggan HM, et al. 1992. Cancer risks from arsenic in drinking water. *Environ Health Perspect* 97:259–267.
- Smith AH, Lingas EO, Rahman M. 2000b. Contamination of drinking water by arsenic in Bangladesh: a public health emergency. *Bull World Health Organ* 78(9):1093–1103.
- Smith AH, Lippiero PA, Bates MN, Steinmaus CM. 2002. Arsenic epidemiology and drinking water standards. *Science* 296(5576):2145–2146.
- Smith AH, Marshall G, Yuan Y, Ferreccio C, Liaw J, von Ehrenstein O, et al. 2006. Increased mortality from lung cancer and bronchiectasis in young adults after exposure to arsenic *in utero* and in early childhood. *Environ Health Perspect* 114:1293–1296.
- Smith AH, Marshall G, Yuan Y, Liaw J, Ferreccio C, Steinmaus C. 2011. Evidence from Chile that arsenic in drinking water may increase mortality from pulmonary tuberculosis. *Am J Epidemiol* 173(4):414–420.
- Smith AH, Steinmaus CM. 2009. Health effects of arsenic and chromium in drinking water: recent human findings. *Annu Rev Public Health* 30:107–122.
- Spivey A. 2011. Arsenic and infectious disease: a potential factor in morbidity among Bangladeshi children [Science Selection]. *Environ Health Perspect* 119:A218.
- States JC, Barchowsky A, Cartwright IL, Reichard JF, Futscher BW, Lantz RC. 2011. Arsenic toxicology:

- translating between experimental models and human pathology. *Environ Health Perspect* 119:1356–1363.
- States JC, Srivastava S, Chen Y, Barchowsky A. 2009. Arsenic and cardiovascular disease. *Toxicol Sci* 107(2):312–323.
- Steinmaus C, Yuan Y, Kalman D, Rey OA, Skibola CF, Dauphine D, et al. 2010. Individual differences in arsenic metabolism and lung cancer in a case-control study in Cordoba, Argentina. *Toxicol Appl Pharmacol* 247(2):138–145.
- Su CC, Lu JL, Tsai KY, Lian le B. 2011. Reduction in arsenic intake from water has different impacts on lung cancer and bladder cancer in an arseniasis endemic area in Taiwan. *Cancer Causes Control* 22(1):101–108.
- Thundiyil JG, Yuan Y, Smith AH, Steinmaus C. 2007. Seasonal variation of arsenic concentration in wells in Nevada. *Environ Res* 104(3):367–373.
- Tseng CH. 2007. Arsenic methylation, urinary arsenic metabolites and human diseases: current perspective. *J Environ Sci Health C Environ Carcinog Ecotoxicol Rev* 25(1):1–22.
- Tseng WP. 1977. Effects and dose–response relationships of skin cancer and blackfoot disease with arsenic. *Environ Health Perspect* 19:109–119.
- U.S. EPA (Environmental Protection Agency). 2001. Arsenic Rule. Washington, DC:U.S. EPA. Available: <http://water.epa.gov/lawsregs/rulesregs/sdwa/arsenic/regulations.cfm> [accessed 2 October 2012].
- Vahidnia A, van der Voet GB, de Wolff FA. 2007. Arsenic neurotoxicity—a review. *Hum Exp Toxicol* 26(10):823–832.
- Vahter M. 2008. Health effects of early life exposure to arsenic. *Basic Clin Pharmacol Toxicol* 102(2):204–211.
- von Ehrenstein OS, Guha Mazumder DN, Hira-Smith M, Ghosh N, Yuan Y, Windham G, et al. 2006. Pregnancy outcomes, infant mortality, and arsenic in drinking water in West Bengal, India. *Am J Epidemiol* 163(7):662–669.
- Wasserman GA, Liu X, Parvez F, Ahsan H, Factor-Litvak P, Kline J, et al. 2007. Water arsenic exposure and intellectual function in 6-year-old children in Araihaazar, Bangladesh. *Environ Health Perspect* 115:285–289.
- Wasserman GA, Liu X, Parvez F, Ahsan H, Factor-Litvak P, van Geen A, et al. 2004. Water arsenic exposure and children's intellectual function in Araihaazar, Bangladesh. *Environ Health Perspect* 112:1329–1333.
- Water Quality Association. 2012. Arsenic. <http://www.wqa.org/siteologic.cfm?ID=2346> [accessed 16 December 2012].
- Watson WH, Yager JD. 2007. Arsenic: extension of its endocrine disruption potential to interference with estrogen receptor-mediated signaling. *Toxicol Sci* 98(1):1–4.
- WHO (World Health Organization). 2005. A field guide for detection, management and surveillance of arsenicosis cases. Geneva:WHO Press. Available: http://www.searo.who.int/LinkFiles/Publications_seaTP30.pdf [accessed 2 October 2012].
- WHO (World Health Organization). 2008. Guidelines for Drinking-water Quality: Incorporating First and Second Addenda to Third Edition. Vol. 1—Recommendations. Geneva:WHO Press. Available: http://www.who.int/water_sanitation_health/dwq/gdwq3/en/index.html [accessed 1 October 2012].
- Winkel LH, Pham TK, Vi ML, Stengel C, Amini M, Nguyen TH, et al. 2011. Arsenic pollution of groundwater in Vietnam exacerbated by deep aquifer exploitation for more than a century. *Proc Natl Acad Sci USA* 108(4):1246–1251.
- Wu MM, Kuo TL, Hwang YH, Chen CJ. 1989. Dose-response relation between arsenic concentration in well water and mortality from cancers and vascular diseases. *Am J Epidemiol* 130:1123–1132.
- Xue J, Zartarian V, Wang SW, Liu SV, Georgopoulos P. 2010. Probabilistic modeling of dietary arsenic exposure and dose and evaluation with 2003–2004 NHANES data. *Environ Health Perspect* 118:345–350.
- Yang Q, Jung HB, Culbertson CW, Marvinney RG, Loiselle MC, Locke DB, et al. 2009. Spatial pattern of groundwater arsenic occurrence and association with bedrock geology in greater Augusta, Maine. *Environ Sci Technol* 43(8):2714–2719.
- Yu G, Sun D, Zheng Y. 2007. Health effects of exposure to natural arsenic in groundwater and coal in China: an overview of occurrence. *Environ Health Perspect* 115(4):636–642.
- Yu HS, Liao WT, Chai CY. 2006. Arsenic carcinogenesis in the skin. *J Biomed Sci* 13(5):657–666.
- Yuan Y, Marshall G, Ferreccio C, Steinmaus C, Liaw J, Bates M, et al. 2010. Kidney cancer mortality: fifty-year latency patterns related to arsenic exposure. *Epidemiology* 21(1):103–108.
- Yuan Y, Marshall G, Ferreccio C, Steinmaus C, Selvin S, Liaw J, et al. 2007. Acute myocardial infarction mortality in comparison with lung and bladder cancer mortality in arsenic-exposed region II of Chile from 1950 to 2000. *Am J Epidemiol* 166(12):1381–1391.